Foghorn Therapeutics Net Worth
Foghorn Therapeutics Net Worth Breakdown | FHTX |
Foghorn Therapeutics Net Worth Analysis
Foghorn Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Foghorn Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Foghorn Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Foghorn Therapeutics' net worth analysis. One common approach is to calculate Foghorn Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Foghorn Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Foghorn Therapeutics' net worth. This approach calculates the present value of Foghorn Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Foghorn Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Foghorn Therapeutics' net worth. This involves comparing Foghorn Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Foghorn Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Foghorn Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Foghorn Therapeutics' net worth research are outlined below:
| Foghorn Therapeutics generated a negative expected return over the last 90 days | |
| Foghorn Therapeutics has high historical volatility and very poor performance | |
| Foghorn Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 34.16 M. Net Loss for the year was (98.43 M) with loss before overhead, payroll, taxes, and interest of (82.3 M). | |
| Foghorn Therapeutics currently holds about 373.5 M in cash with (118.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.94, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Foghorn Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 73.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Acquisition by Carlos Costa of 857 shares of Foghorn Therapeutics at 3.72 subject to Rule 16b-3 |
Foghorn Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Foghorn Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Foghorn Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Foghorn Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Foghorn Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Foghorn Therapeutics backward and forwards among themselves. Foghorn Therapeutics' institutional investor refers to the entity that pools money to purchase Foghorn Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | |||
| State Street Corp | 2024-12-31 | 567.4 K | |
| Alphabet Inc | 2024-12-31 | 500.9 K | |
| Birchview Capital, Lp | 2024-09-30 | 320.9 K | |
| Northern Trust Corp | 2024-12-31 | 253.7 K | |
| Jacobs Levy Equity Management, Inc. | 2024-12-31 | 223.8 K | |
| Dafna Capital Management Llc | 2024-12-31 | 186.7 K | |
| Sio Capital Management, Llc | 2024-12-31 | 121.7 K | |
| D. E. Shaw & Co Lp | 2024-12-31 | 100.4 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 97.5 K | |
| Flagship Ventures Management, Inc. | 2024-12-31 | 12.7 M | |
| Fmr Inc | 2024-12-31 | 5.7 M |
Follow Foghorn Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 269.72 M.Market Cap |
|
Project Foghorn Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.31) | (0.33) | |
| Return On Capital Employed | (0.43) | (0.45) | |
| Return On Assets | (0.31) | (0.33) | |
| Return On Equity | 1.47 | 1.54 |
When accessing Foghorn Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Foghorn Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Foghorn Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Foghorn Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Foghorn Therapeutics. Check Foghorn Therapeutics' Beneish M Score to see the likelihood of Foghorn Therapeutics' management manipulating its earnings.
Evaluate Foghorn Therapeutics' management efficiency
Foghorn Therapeutics has return on total asset (ROA) of (0.2045) % which means that it has lost $0.2045 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.7038) %, meaning that it created substantial loss on money invested by shareholders. Foghorn Therapeutics' management efficiency ratios could be used to measure how well Foghorn Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 1.54 in 2025, whereas Return On Tangible Assets are likely to drop (0.33) in 2025. At this time, Foghorn Therapeutics' Debt To Assets are fairly stable compared to the past year. Fixed Asset Turnover is likely to rise to 0.75 in 2025, whereas Total Assets are likely to drop slightly above 280.8 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (1.66) | (1.57) | |
| Tangible Book Value Per Share | (1.66) | (1.57) | |
| Enterprise Value Over EBITDA | (2.03) | (2.13) | |
| Price Book Value Ratio | (3.16) | (3.00) | |
| Enterprise Value Multiple | (2.03) | (2.13) | |
| Price Fair Value | (3.16) | (3.00) | |
| Enterprise Value | 270.8 M | 502.4 M |
Understanding the operational decisions made by Foghorn Therapeutics management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Enterprise Value Revenue 1.6441 | Revenue | Quarterly Revenue Growth (0.55) | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Foghorn Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Foghorn Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Foghorn Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Foghorn Therapeutics Corporate Filings
| 12th of February 2025 Other Reports | ViewVerify | |
8K | 3rd of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 8th of October 2024 An amended filing to the original Schedule 13G | ViewVerify |
F4 | 24th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Foghorn Therapeutics Earnings per Share Projection vs Actual
Foghorn Therapeutics Corporate Management
| Karin Hellsvik | Corporate VP | Profile | |
| Saurabh Sewak | Vice Development | Profile | |
| Kristian MBA | Chief Officer | Profile | |
| Allan MD | Chief Officer | Profile | |
| Alfonso MD | Chief Officer | Profile |
Additional Tools for Foghorn Stock Analysis
When running Foghorn Therapeutics' price analysis, check to measure Foghorn Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Foghorn Therapeutics is operating at the current time. Most of Foghorn Therapeutics' value examination focuses on studying past and present price action to predict the probability of Foghorn Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Foghorn Therapeutics' price. Additionally, you may evaluate how the addition of Foghorn Therapeutics to your portfolios can decrease your overall portfolio volatility.